Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Incompetent CEO
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(178)
•••
Comment by Layth1990on Mar 05, 2021 2:04pm
119 Views
Post# 32729858

RE:RE:RE:RE:RE:RE:RE:Incompetent CEO

RE:RE:RE:RE:RE:RE:RE:Incompetent CEO

To he honest, nothing is guaranteed. Good phase 2 results, we got Dumped from 8.9cad to 4cad in one day. We got the best deal with nuance, then Suspecious buy before 2 days of the announcement then dumped. We are supposed to be now at 10+ after the deal. We were 8.9 at phase 2.  

investors are getting pushed away, my trust is totally gone in ceo/directors but not in the science. I come from a scientic background and i know the issue isnt from the science. We have a good nuance deal, bank full with money and fully funded phase 3. Sp 4.5 cad lol. why am i investing here thenand who said it wont get dumped even after good phase 3 results. We have seen it all! 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities